ESMO 2022
Data Read-out



INVESTOR RELATIONS 2022

NEOIMMUNETECH

September 13, 2022

Disclaimer

This document has been prepared by NeoImmuneTech, Inc. (the "Company") solely for informational purpose as a presentation to investors and is strictly prohibited to be passed on, copied, or redistributed.

By participating in this presentation, the recipient of information hereby acknowledges and agrees to comply with the aforementioned restrictions, and such violations are subject to a violation of the Capital Market and Financial Investment Act. Projections contained in this document have not been subjected to individual verifiers. They are predictions of future, not past, events. This document explains the Company's anticipated business and financial performance, and includes expressions such as "anticipation", "forecast", "plan", "expectation", and "(E)".

The aforementioned "forecasted information" is influenced by future changes in the business environment and by definition contain uncertainties. Due to this inherent uncertainty, actual performance in the future may differ from what is stated or implied in the "forecasted information" presented in this document. Moreover, future forecasts in this presentation have been prepared given the current market situation and the Company's management direction and is subject to change depending on changes in either the market situation or strategy. The information presented or contained in these materials is subject to change without notice.

We are not responsible for any losses incurred in connection with the use of this material, including negligence or otherwise, by our employees. This document does not constitute solicitation for the recruitment, sale, or subscription of shares and no part of the document shall constitute an invitation to relevant contracts and arrangements or investment decisions.

NEOIMMUNETECH

Poster Presentation at ESMO

GOOD SCIENCE
BETTER MEDICINE
BEST PRACTICE

European Society for Medical Oncology

1. NIT-110 Biomarker data (Ph.2a) Poster 1674P

- Biomarker data from the CPI-naïve arms: MSS-CRC, PaC and Ovarian cancer

Poster title:

NT-I7 plus pembrolizumab combination treatment enhances infiltration of PD-1+ T cells and provides a more immunogenic tumor microenvironment. Biomarker data from the NIT-110 study

ESMO Key messages

For the first time in a clinical trial, biomarker analysis showed enhanced tumor microenvironment (TME) immunogenicity and suggested that T cells induced to infiltrate the TME by **NT-I7** *are tumor-specific*

1. **Biomarker data from tissue biopsy shows that the biological mechanism is linked to efficacy of pembro + NT-I7 combo in immune-cold tumors**
2. **Expansion of CD8 Tscm may be the source of T cell infiltration**
3. **Data suggests infiltrating lymphocytes may include tumor-specific CD8 T cells**
4. **A more immunogenic TME is directly associated with tumor reduction**
   - the increase in the CD8-to-Treg ratio was particularly remarkable in pts with PR

Increased TIL in TME

- Pembro + NT-I7 combo favors infiltration of CD8 T cells into the TME in over 80% of analyzed tissue samples (22/27 pts)
- Over 50% of pts had a significant, over 5-fold, CD8 T cell increase after the first dose of NT-I7



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

Increased Tscm associated with T cell infiltration

- The absolute number of **peripheral CD8 Tscm at week 3** is directly associated with the absolute number of **intratumoral CD8 T cells at week 5** (n = 12)
- Among all T cell subsets, CD8 Tscm are more strongly associated with the CD8 T cell infiltration into the tumor



* Absolute number

Increased tumor-specific CD8 T cells in the TME

- Tumor-infiltrating CD8 T cells express PD-1 (n = 12), suggesting that tumor-specific CD8 T cells successfully infiltrate the TME

Tumor-infiltrating CD8 T cells express PD-1



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

Enhanced clonality and diversity

- Pts with disease control (PR+SD) show a greater increase in intratumoral clonality than PD pts
- Increase in intratumoral clonality in the 2 PR pts was uniquely accompanied by an increase in intratumoral diversity

Intratumoral clonality



Intratumoral clonality, diversity



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

Note: T cell repertoire (clonality and diversity)

- TCR repertoire metrics includes diversity and clonality
- The analysis of the TCR repertoire has been recently considered to be a potential biomarker for patients' progression and response to therapies with immune checkpoint inhibitors

Repertoire

Clonality

- **Tumor-specific** clones are overrepresented
- Higher clonality suggests higher anticancer activity



Diversity

- **More clones** are present (tumor-specific or not)
- Higher diversity increases the ability to recognize various types of tumor cells



Source: Wang, X., et al., Journal for ImmunoTherapy of Cancer, 2022; 10(6), e004512.
Aran, A., et, al., Cancers, 2020; 14(7), 1771.

Increased immunogenicity (1)

- The number of CD8 T cells is significantly increased and CD8-to-Treg ratio is increased in PR pts (n = 12)
- Pembro+NT-I7 combo increases the number of CD8 T cells per tumor cell (n = 15)



* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001

Increased immunogenicity (2)

- Magnitude of CD8 T cell infiltration is directly associated with tumor reduction (n = 12)
- CD8-to-Treg ratio at week 5 is significantly associated with the tumor reduction (n = 12)

CD8 T cell infiltration



CD8-to-Treg ratio*



* On-treatment sample from an additional PR was available for this analysis

Summary of scientific findings

1) Safety in both mono & combo therapies has been confirmed from 600+ pts

2) Tscm, which have a strong anti-tumor effect, were selectively and strongly amplified

3) Increase in TIL was clinically observed for multiple cancer types

4) TIL increased proportionally to Tscm (clinically observed)

5) Increases in TIL and the intratumoral CD8-to-Treg ratio led to improved clinical response

Summary of competitiveness of NT-I7

1) The world's most clinically tested T cell amplifier

- Strong and selective T cell amplification effects are consistently observed
- Less side effects, high tolerability and safety profile

2) Promising and unique partner for CPI therapy

- Excellent synergistic effects with CPI were observed in non-clinical studies
- Excellent therapeutic efficacy was clinically observed in immune-cold tumors that had minimal efficacy with CPI alone (PaC and MSS-CRC)

3) A key player in various combination therapies in the immuno-oncology field

- Like PD-1 therapies, NT-I7 has the potential to play a central role in T cell-based therapies
- The most advanced clinical stage interleukin-7 pipeline with a safety profile
- Potential to become 1L, 2L, or 3L triple combo therapy where chemotherapy is the standard of care (i.e., chemotherapy + CPI + NT-I7 triple combo)
- As a strong and yet selective T cell booster, it can play an important role in various combo therapies

NT-I7 development status

- After PoC is demonstrated from 1b/2a studies, a pivotal study design will be prepared



1. ALC: AACR 2018, AACR 2019, SITC 2019, ASCO 2020, SITC 2020, ASCO 2021, SNO 2021, ITC 2021, AACR 2022,
   Kim JH et al. Clinical & Translational Immunology; e1168 (2020), Campian JL. et al. Clin Cancer Res. 2022 Mar 15;28(6):1229-1239.
2. Tscm: SITC 2021, ASCO 2022
3. TIL: ASCO 2021, SITC 2021, ESMO GI 2022
   Kim JH et al. Clinical & Translational Immunology; e1168 (2020)
4. Tpex: AACR 2022

Upcoming major events for 2H 2022

Estimated Data Read-Outs	**(SITC)** NIT-110: Selected cohorts, Pembrolizumab combo **(ASH)** NIT-112: LBCL, CAR-T combo	Interim Analysis

* Data read-out plans are subject to change

- Society for Immunotherapy of Cancer (SITC)
- Nov. 8 – Nov. 12, Boston, MA
- Oral presentation for NIT-110 / Nov.11 4:20 p.m.

- American Society of Hematology (ASH)
- Dec. 10 – Dec. 13, New Orleans, Louisiana
- NIT-112 data

Appendix: NIT-110 study protocol

- CPI-naïve R/R solid tumors
- Pembrolizumab IV (Q3W; 200mg) + NT-I7 IM (Q6W; 1,200 μg/kg)





Primary Objectives

- ORR (Objective Response Rate)

THANK YOU !

NeoImmuneTech

[Korea Office] C-1003, Innovalley 253, Pangyo-ro, Bundang-gu,
Seongnam-si, Gyeonggi-do, Republic of Korea
ir@neoimmunetech.com

[Headquarters] 2400 Research Blvd., Suite 250, Rockville, MD 20850, USA
ir@neoimmunetech.com